GSK plc (GSK) ORD GBP0.3125
- Add to watchlist
- Create an alert
- This stock can be held in a
Share news, reports & tips
-
GSK reports positive results from ovarian cancer drug trial
20 December 2024 07:12
(Sharecast News) - GSK has announced positive results from a phase III trial of its ovarian cancer treatment, which met its primary endpoint of progression free survival.
-
EU recommends expanding use of GSK endometrial cancer drug
16 December 2024 07:04
(Sharecast News) - GSK said the European Union's Committee for Medicinal Products for Human Use has recommended expanding approval of Jemperli in combination with chemotherapy for treatment of adults...
-
GSK says US agrees to look at data for new use of COPD drug
9 December 2024 07:06
(Sharecast News) - GSK said the US Food and Drug Administration has agreed to look at data from its MATINEE study to support the regulatory review process to obtain a new use of its Nucala drug as an add-on...
-
GSK extends strategic vaccine collaboration with Zhifei
5 December 2024 09:37
(Sharecast News) - Drugmaker GSK has revised and extended its strategic vaccine collaboration with Chinese firm Chongqing Zhifei Biological Products.
-
Berenberg lowers target price on GSK
2 December 2024 11:36
(Sharecast News) - Analysts at Berenberg lowered their target price on drugmaker GSK from £18.20 to £16.00 on Monday after hosting chief financial officer Julie Brown at its 2024 Pharma CFO series.
-
GSK's liquid meningitis vaccine approved by EU regulators
27 November 2024 07:18
(Sharecast News) - GSK's liquid meningitis vaccine Menveo has been approved by EU regulators, paving the way for a simpler vaccination process against invasive meningococcal disease (IMD).
-
GSK's liquid meningitis vaccine approved by EU regulators
27 November 2024 07:18
(Sharecast News) - GSK's liquid meningitis vaccine Menveo has been approved by EU regulators, paving the way for a simpler vaccination process against invasive meningococcal disease (IMD).
-
GSK's Blenrep treatment accepted for review by FDA
25 November 2024 07:55
(Sharecast News) - Pharma titan GSK has announced that US regulators have accepted for review Blenrep combinations for the treatment of relapsed or refractory multiple myeloma.
-
GSK's Arexvy approved for wider age range in Japan
22 November 2024 07:17
(Sharecast News) - Biopharma giant GSK has announced that Japanese regulators have expanded the approved use of its Arexvy vaccine for severe respiratory syncytial virus (RSV) disease to a wider age range.
-
GSK's linerixibat meets primary endpoint
19 November 2024 09:21
(Sharecast News) - Drugmaker GSK said on Tuesday that its linerixibat candidate had shown "positive" Phase III results in cholestatic pruritus in primary biliary cholangitis.
-
London close: Stocks end turbulent week in the red
15 November 2024 15:21
(Sharecast News) - London stocks ended Friday in negative territory, weighed down by losses in pharmaceutical shares and a surprise slowdown in UK economic growth during the third quarter.
-
GSK's Blenrep shows strong survival benefit in myeloma study
14 November 2024 07:26
(Sharecast News) - GSK reported positive results from its phase three 'DREAMM-7' trial on Thursday, highlighting a significant overall survival benefit for 'Blenrep', or belantamab...
Company announcements Announcements
-
Block Listing Application
20 December 2024 09:00
GSK
-
Headline results from phase III FIRST trial
20 December 2024 07:00
GSK
-
Jemperli receives US FDA breakthrough designation
16 December 2024 07:11
GSK
-
EMA grants PRIME Designation for GSK’227
16 December 2024 07:05
GSK
-
Jemperli receives positive CHMP opinion
16 December 2024 07:00
GSK
-
Director/PDMR Shareholding
12 December 2024 15:30
GSK
-
Overall survival data presented for Blenrep
9 December 2024 18:29
GSK
-
Blenrep combination China filing acceptance
9 December 2024 07:05
GSK
-
Nucala COPD submission accepted by US FDA
9 December 2024 07:00
GSK
-
Zhifei China collaboration revised and extended
5 December 2024 07:00
GSK
-
Director/PDMR Shareholding
2 December 2024 15:30
GSK
-
GSK liquid meningitis vaccine authorised in EU
27 November 2024 07:00
GSK
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.